Ledipasvir/Sofosbuvir
Sponsors
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Humanity and Health Research Centre, University Health Network, Toronto, Catherine Chappell, Parc de Salut Mar
Conditions
Chronic Hepatitis CChronic Hepatitis C InfectionCirrhosisCirrhosis, DecompensatedGaucher DiseaseHBV CoinfectionHCVHIV-1 Infection
Phase 1
Phase 2
DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
CompletedNCT02555943
Start: 2015-02-28End: 2021-08-31Updated: 2021-09-01
12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
TerminatedNCT02605304
Start: 2016-02-17End: 2017-03-20Updated: 2018-05-02
Phase 3
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
CompletedNCT02576314
Start: 2015-05-31End: 2018-03-15Updated: 2018-03-19
Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection
CompletedNCT02597166
Start: 2016-01-31End: 2018-06-30Updated: 2018-10-25